InvestorsHub Logo
Followers 38
Posts 9413
Boards Moderated 0
Alias Born 05/12/2006

Re: None

Saturday, 04/15/2017 9:10:23 PM

Saturday, April 15, 2017 9:10:23 PM

Post# of 215
Aptevo will be speaking Thursday, May 4, at the PEGSummit.

Innovative Engineering Approaches to Improve Drug
Efficacy
11:05 From the Bench to the Clinic: Developing Next-Generation
ADAPTIRTM Molecules
Peter Pavlik, Ph.D., Principal Scientist, Molecular Biology & Protein Engineering,
Aptevo Therapeutics
The ADAPTIRTM (modular protein technology) platform of bispecific protein
therapeutics has unique properties compared to other bispecific antibody formats.
A pipeline of ADAPTIR therapeutics is currently under development from early
discovery to clinical stage, targeting both solid and hematologic malignancies.
Updates will be provided on advanced ADAPTIR therapeutics, including MOR209/
ES414 and ES425.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent APVO News